Anzeige
Meldung des Tages: Startschuss in Nevada: Dieser Kupfer-Explorer könnte vom US-Rohstoffboom profitieren

AbbVie News

Aktie
WKN:  A1J84E ISIN:  US00287Y1091 US-Symbol:  ABBV Branche:  Pharmazeutika Land:  USA
221,45 $
+0,00 $
0,00%
192,66 € 17.03.26
Depot/Watchlist
Marktkapitalisierung *
345,80 Mrd. €
Streubesitz
24,69%
KGV
21,69
Dividende
5,85 EUR
Dividendenrendite
3,02%
Nachhaltigkeits-Score
46 %
Index-Zuordnung
S&P 500
Weiter aufwärts? Long handeln - Jetzt mit Hebel 20,28: MN32BT
Werbung

AbbVie News

29.10.25 - PR Newswire
AbbVie Announces Positive Topline Results from Phase 3 Pivotal Studies Evaluating Upadacitinib (RINVOQ®) in Adults and Adolescents with Vitiligo
AbbVie Announces Positive Topline Results from Phase 3 Pivotal Studies Evaluating Upadacitinib (RINVOQ®) in Adults and Adolescents with Vitiligo PR Newswire
28.10.25 - PR Newswire
Allergan Aesthetics and Girls Inc., in Partnership with SkinSpirit, Inspire Future Women Leaders in STEM
Allergan Aesthetics and Girls Inc., in Partnership with SkinSpirit, Inspire Future Women Leaders in STEM PR Newswire
26.10.25 - wallstreetONLINE Redaktion
Earnings Preview – Teil 2: Hohe Bewertungen erlauben keine Fehler: Amazon, Apple und Co. müssen liefern!
Diese in den kommenden Tagen (KW44) anstehenden US-​Quartals­zahlen müssen Anlegerinnen und Anleger kennen: Herausforderungen, Erwartungen und die aktuell ...
21.10.25 - PR Newswire
The Confidence Project by BOTOX® Cosmetic (onabotulinumtoxinA) Unveils This Year's Grant Recipients
The Confidence Project by BOTOX® Cosmetic (onabotulinumtoxinA) Unveils This Year's Grant Recipients PR Newswire
20.10.25 - PR Newswire
RINVOQ® (upadacitinib) Demonstrated Superiority Versus HUMIRA® (adalimumab) for Primary Endpoint in a Head-to-Head Study in Rheumatoid Arthritis Patients Who Have Failed First TNF Inhibitor
RINVOQ® (upadacitinib) Demonstrated Superiority Versus HUMIRA® (adalimumab) for Primary Endpoint in a Head-​to-Head Study in Rheumatoid Arthritis Patients Who Have Failed ...
17.10.25 - PR Newswire
AbbVie Completes Acquisition of Gilgamesh Pharmaceuticals' Bretisilocin
AbbVie Completes Acquisition of Gilgamesh Pharmaceuticals' Bretisilocin PR Newswire
13.10.25 - PR Newswire
U.S. Food and Drug Administration (FDA) Approves Updated Indication Statement for RINVOQ® (upadacitinib) for the Treatment of Inflammatory Bowel Disease
U.S. Food and Drug Administration (FDA) Approves Updated Indication Statement for RINVOQ® (upadacitinib) for the Treatment of Inflammatory Bowel Disease PR Newswire
13.10.25 - PR Newswire
AbbVie to Present New Data at ESMO 2025 Reinforcing Leadership in Advancing Targeted Therapies for Solid Tumors
AbbVie to Present New Data at ESMO 2025 Reinforcing Leadership in Advancing Targeted Therapies for Solid Tumors PR Newswire
09.10.25 - PR Newswire
SkinMedica® Debuts Reimagined Packaging and Unveils New HA5® Hydra Collagen Water Burst Moisturizer
SkinMedica® Debuts Reimagined Packaging and Unveils New HA5® Hydra Collagen Water Burst Moisturizer PR Newswire
06.10.25 - Société Générale
AbbVie – Verschnaufpause nach Rally
Die  AbbVie -Aktie (WKN: A1J84E) bewegt sich in allen relevanten Zeitebenen in einem  intakten Aufwärtstrend . Der letzte mittelfristige Kursschub beförderte sie vom April-​Tief bei ...
06.10.25 - PR Newswire
AbbVie Announces Positive Topline Results from Phase 2 ELATE Trial Evaluating OnabotulinumtoxinA (BOTOX®) for the Treatment of Upper Limb Essential Tremor
AbbVie Announces Positive Topline Results from Phase 2 ELATE Trial Evaluating OnabotulinumtoxinA (BOTOX®) for the Treatment of Upper Limb Essential Tremor PR Newswire
02.10.25 - PR Newswire
AbbVie to Host Third-Quarter 2025 Earnings Conference Call
AbbVie to Host Third-​Quarter 2025 Earnings Conference Call PR Newswire
01.10.25 - wallstreetONLINE Redaktion
Aktien kräftig im Plus: Medikamenten-Deal entfesselt Pharma-Aktien
Die Aktienkurse großer US-​Pharmaunternehmen haben am Dienstag kräftig zugelegt, nachdem Präsident Donald Trump eine Vereinbarung mit Pfizer bekanntgab.Pfizer senkt ...
01.10.25 - PR Newswire
Natrelle® Awarded Supplier Agreement from Vizient
Natrelle® Awarded Supplier Agreement from Vizient PR Newswire
30.09.25 - PR Newswire
AbbVie Begins Construction on $70 Million Expansion to Further Increase Biologics Manufacturing and R&D Presence in the U.S.
AbbVie Begins Construction on $70 Million Expansion to Further Increase Biologics Manufacturing and R&D Presence in the U.S. PR Newswire
30.09.25 - PR Newswire
AbbVie Submits Biologics License Application (BLA) to U.S. FDA for Pivekimab sunirine (PVEK) - an Investigational Antibody-Drug Conjugate (ADC) to Treat Rare Cancer with Limited Treatment Options
AbbVie Submits Biologics License Application (BLA) to U.S. FDA for Pivekimab sunirine (PVEK) - an Investigational Antibody-​Drug Conjugate (ADC) to Treat Rare Cancer with ...
29.09.25 - PR Newswire
AbbVie Breaks Ground on New North Chicago Active Pharmaceutical Ingredient Manufacturing Facility
AbbVie Breaks Ground on New North Chicago Active Pharmaceutical Ingredient Manufacturing Facility PR Newswire
29.09.25 - PR Newswire
AbbVie Announces UK Pricing Strategy for ELAHERE® (mirvetuximab soravtansine-gynx)
AbbVie Announces UK Pricing Strategy for ELAHERE® (mirvetuximab soravtansine-​gynx) PR Newswire
26.09.25 - PR Newswire
AbbVie Submits New Drug Application to U.S. FDA for Tavapadon for the Treatment of Parkinson's Disease
AbbVie Submits New Drug Application to U.S. FDA for Tavapadon for the Treatment of Parkinson's Disease PR Newswire
25.09.25 - PR Newswire
Allergan Aesthetics to Showcase Multimodal Treatment Approach and Continued Commitment to Skin Quality at AMWC Dubai
Allergan Aesthetics to Showcase Multimodal Treatment Approach and Continued Commitment to Skin Quality at AMWC Dubai PR Newswire

Newssuche

Videos

newspaper
16.03.26 +4,81%
Technical Trading: 82 Prozent Trefferquote
S&P 500 Long Typ: Open End Turbo WKN: VG93RW Hebel: 5 Laufzeit: OpenEnd Einstieg: Market ... Mehr »